MAR 20, 2018 11:10 PM PDT

The 'Molecular Key' in Developing Tuberculosis Drugs

WRITTEN BY: Nouran Amin
3 4 154

Tuberculosis is an ancient disease, signs of it were examined in Egyptian mummies. It is caused by the bacterium and pathogen, Mycobacterium tuberculosis, which infects about one quarter of the world's population killing roughly two million individuals per a year. Despite how ancient the disease is, the pathogen that causes Tuberculosis.

Now, research performed by scientists at the University of Rockefeller which is directed by Seth Darst and Elizabeth Campbell, a researcher in the Darst's laboratory, may challenge the evolutionary traits of M. tuberculosis offering a strong and potent treatment against the disease. The particular research has focused on an antibiotic that eradicates M. tuberculosis in a laboratory environment which is not suitable for clinical use. The researcher's work has aimed to explain how this new treatment operates which can encourage other investigators to develop new antibiotics to effectively treat tuberculosis patients.

Image via University of Cambridge

The discovered drug treatment was an antibiotic known as fidazomicin, which successfully kills M. tuberculosis. However, for fidazomicin to be effective against the treatment of tuberculosis in a real-world setting, it must be absorbed by the gut, and to do that researchers must understand its molecular mechanism.

Fidaxomicin works to inhibit an enzyme called RNA polymerase (RNAP), which helps transcribe DNA into RNA, a fundamental process of life. The enzyme, RNA polymerase, was seen to include hinged pincer that works to close down for secure DNA transcription. Therefore, investigators believe that fidaxomicin can interfere with the hinged pincer of the RNA polymerase, they just not yet understand how the interference occurs and if fidaxomicin holds inhibiting properties such knowledge may pride more versions of fidaxomicin for maximum efficacy against tuberculosis.

Through the use of an imaging technique known as cryo-electron microscopy, investigators were able to figure out exactly how the antibiotic works against RNAP. In early studies, they found out that a version of RNAP found in M. tuberculosis works only when combined with a protein known as RbpA; a transcription factor present in few bacteria. The transcription factor, RbpA, forms itself into a small pocket located at the base of the RNAP hinged pincer, allowing full functionality. Using cryo-electron microscopy, Hande Boyaci (a post-doc) and James Chen (graduate student) were able to make it evident that fidaxomicin binds to RbpA and other parts of the RNAP deep inside that pocket. "It acts like a doorstop, and prevents the clamp from securing DNA for transcription," says Elizabeth Campbell.

Furthermore, the research team took it a step furthers to work with a non-pathogenic cousin of M. tuberculosis; which is M. smegmatis. In particular, they used a mutant form of the bacterium that have a portion of the RbpA that is necessary for interaction with fidaxomicin. If the normal Mycobacteria was exposed to fidaxomicin, then the bacterium will not grow. On the other hand, the mutant forms were successful in dividing and thriving despite the presence of an antibiotic. This concluded that RbpA is essential in part of the mechanism which allows these un-mutated forms of Mycobacteria to be vulnerable to fidaxomicin.

"Our hope is that drug companies will use these studies as a platform for modifying and designing antimicrobials," says Campbell. "They could use the structures we analyzed to design antibiotics that would only inhibit Mycobacteria, but they could probably also design broad-spectrum antibiotics that would kill a wide range of other bacteria."

Sources: eLife, Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAR 01, 2018
Drug Discovery
MAR 01, 2018
The 24 hour Flu-Killing Drug
A pharmaceutical company, Shinogi, in Japan has developed an experimental drug that may kill the flu virus in as little as 24 hours.
MAR 05, 2018
Drug Discovery
MAR 05, 2018
First Medication Claimed to Treat Symptoms of Autism Enters Clinical Trial
A recently developed drug may be the first medication to treat symptoms of autism and increase the ability of autistic individuals to connect with others. This drug is known as balovaptan whi
MAR 11, 2018
Drug Discovery
MAR 11, 2018
New Drug for Multiple Sclerosis? Potential Therapeutic Treatment Uncovered
Multiple sclerosis (MS) is a neurological disease that is unpredictable and often disabling in affected individuals. It is more specifically a disease of t
APR 15, 2018
Drug Discovery
APR 15, 2018
Monoclonal Antibody May Serve as Treatment for Malaria
A study published in Nature Medicine examines a monoclonal antibody isolated from the blood of individuals vaccinated for malaria and its potential role in
MAY 03, 2018
Drug Discovery
MAY 03, 2018
Treating Migraines with Less Side-Effects
According to a 2013 Global Burden of Disease Study and the World Health Organization (WHO), migraine makes the list as the sixth highest cause worldwide fo
JUN 20, 2018
Drug Discovery
JUN 20, 2018
New Drug 'Moxidectin' for River Blindness
A new treatment to help eliminate a neglected tropical disease was developed thanks in part to an incentive program devised by researchers at Duke Universi
Loading Comments...